TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells (Adv. Sci. 5/2026)
Source abstract
Abstract
Anti-Tumor Immunity TREM2+ TAMs promote tumor growth by suppressing anti-tumor immunity. Blockade of TREM2 reprograms macrophages, increases the infiltration and activity of CD4+ T and NK cells, thereby enhancing the anti-tumor responses. Bortezomib and ataluren, FDA-approved drugs, effectively enhance anti-tumor efficacy by inhibiting TREM2 to reshape the tumor microenvironment, indicating a potential therapeutic strategy for cancer. More details can be found in the Research Article by Li Yang, Yi Zhang, and co-workers (DOI: 10.1002/advs.202506995).
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Inflammation biomarkers and pathways · Neuroinflammation and Neurodegeneration Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References
Reference metadata was not supplied for this record.